Whole antibodies have grabbed a significant share of the global sales revenue as well as the volume of the biopharmaceuticals market. But with recent research and development efforts, it has come to light that the whole or full-length antibodies may always not be needed, or sometimes may not be desirable even for therapeutic use. Antibody fragments come in the picture at this point. For example, anti-tumor antibodies are larger in size and therefore can’t penetrate the tumor, thus affecting their therapeutic value in tumor suppression. Antibodies are also inappropriate for intracellular targeting sites because of their comparatively larger size. In this case, antibody fragments having specific sequences for the target site is used. Antibody fragments show enhanced penetration due to their smaller size. Antibody fragments can bind at highly specific sites and they can be manufactured or designed without the Fc region thus eliminating immunogenicity. Also, the antibody fragments have low manufacturing cost, high yield in production and extended therapeutic uses.
Antibody Fragments Market: Segmentation
On the basis of product type, the antibody fragments market can be segmented into,
- F(ab) fragment
- F(ab’)2 fragment
On the basis of disease indication, the antibody fragments market can be segmented into,
On the basis of region, the antibody fragments market can be segmented into,
- North America
- Asia Pacific
- Latin America
- Middle East Africa
Firstly, antibody fragments are segmented into F(ab) fragment and F(ab’)2. A papain digestion of an antibody will yield two F(ab) fragments. F(ab) fragment is a monovalent antibody structure devoid of the Fc region but has an antigen binding site. The F(ab) fragments are used to block the endogenous Ig's-immunoglobulins. However, F(ab’)2 fragments are obtained through the pepsin digestion of IgG antibody. This digestion will remove most of the Fc region but will keep some of the hinge region intact. This fragment has two antigen binding sites which are attached by disulfide bonds. The F(ab’)2 fragments are smaller in size and thus have better penetration. This antibody fragment also has a better antigen recognition feature, as these antibody fragments avoid unspecific binding. Both of these antibody fragments provide better results in the immunohistochemistry applications. Antibody fragments have a very vast range of therapeutic applications. The field of antibody fragments applications is just the revised or advanced version of monoclonal antibody therapeutic applications. Antibody fragments are very useful in medical diagnostics; specific antibody fragments are used for disease diagnosis. In some cases, multiple antibody fragments are used to spot antigens specific to cause a particular infectious disease. Antibody fragments are used to treat many immune deficiencies, central nervous system disorders, and cardiovascular diseases. Many antibody fragments are used to treat colorectal cancer and breast cancer.
Antibody Fragments Market: Market Dynamics
With increasing incidences of various types of cancers, infectious diseases and in turn immune deficiencies, there is going to be an increasing demand for antibody fragments. Also, an increase in geriatric population has been observed worldwide. Therefore, looking at the application prospects of antibody fragments, the market is likely to boom over the forecast period. Antibody fragments are also expected to be preferred compared to full-chain antibodies as the manufacturing and purification costs of antibody fragments are less. Strict ICD-10 guidelines may restrain the use of some antibody fragments for the treatment of a particular disease. However, new developments in the clinical development of antibody fragments for some of the deadliest diseases can give a massive opportunity for the antibody fragments market over the forecast period.
Antibody Fragments Market: Region-wise Outlook and Key Players
The occurrence of cancer and other immunodeficiencies are observed at a higher rate in North America compared to other regions. North America and Europe spend a significant amount of money on drugs and therapies related to cancer. It is estimated that North America is the largest market for antibody fragments, followed by Europe, trailed by Asia-Pacific, Latin America and the Middle East and Africa. The key players in the antibody fragments market are Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Takeda Pharmaceutical Company Limited, Sanofi, Biogen Inc. and Eli Lilly and Co.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.